|
|
 |
|
Viewing report
|
|
|
|
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
CurrentPartnering, June 2009, Pages: 471
The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the oncology partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery, preclinical or clinical whereby the licensee obtains a right or an option right to license the licensors oncology technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, licensing of outcomes and often retention by the licensor of co-promotion rights.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains over 900 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Key benefits
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
- In-depth understanding of oncology deal trends since 2000
- Analysis of the structure of oncology agreements with numerous real life case studies
- Comprehensive access to over 900 actual oncology contracts entered into by the world’s biopharma companies*
- Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies*
- Insight into the terms included in a oncology agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
*Subject to being published via regulatory requirements of the Securities Exchange Commission.
Report scope
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the oncology trends and structure of deals entered into by leading biopharma companies worldwide. Oncology Partnering Agreements in Pharma, Biotech and Diagnostics includes:
- Trends in oncology dealmaking in the biopharma industry since 2000
- Analysis of oncology deal structure
- Case studies of real-life oncology deals
- Access to over 900 oncology contract documents
- The leading oncology deals by value since 2000
- Most active oncology dealmakers since 2000
- The leading oncology partnering resources
In Oncology Partnering Agreements in Pharma, Biotech and Diagnostics, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific oncology target
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for over 900 oncology deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise oncology rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Customers who bought this item also bought
Pre-clinical Stage Partnering Agreements in Biopharma
Clinical Stage Partnering Agreements in Biopharma
Discovery Stage Partnering Agreements in Biopharma
Drug Delivery Partnering Agreements in Pharma and Biotech
Manufacturing and Supply Agreements in Biopharma
Distribution Agreements in Biopharma
Royalty Financing Agreements in Pharma, Biotech and Diagnostics
Option and Evaluation Agreements in Pharma and Biotech
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Co-promotion and Co-marketing Agreements in Biopharma, 2nd Edition
Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Strategic Perspectives: Oncology licensing strategies - how will targeted therapies affect the licensing market?
|
|
|
|
